Medifast stock gains 2.62 percent as Q2 losses narrow

Published on 10/04/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medifast stock posted Q2 2026 revenue of USD 76.38 million on August 3, 2026, with a narrower-than-expected loss. Revenue fell 27.6 percent year over year, while the USD 12.00 consensus target sits above the latest quote.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast stock (ISIN US58470H1014) was last at USD 11.73 on the NYSE on October 2, 2026 at 4:00 p.m. ET, up 2.62 percent on the session. The move followed a Q2 2026 report in which the company posted a loss per share of USD 0.28, beating the USD 0.65 consensus loss by USD 0.37, according to MarketBeat on October 3, 2026.

Q2 revenue falls 27.6 percent

Revenue reached USD 76.38 million in Q2 2026, down 27.6 percent from USD 105.6 million in Q2 2025, while the result exceeded the USD 72.70 million analyst estimate, Zacks reported on September 2, 2026. The result shows the central tension in the turnaround: revenue is contracting, but earnings per coach are improving.

Average revenue per active earning coach increased 41 percent year over year to USD 6,529 from USD 4,630 in Q2 2026, according to Zacks. The improvement came as active earning coaches fell 48.7 percent to 11,700 from 22,800 a year earlier.

Reduce consensus stays cautious

MarketBeat reported on October 3, 2026 that two analysts rate Medifast Hold and one rates it Sell, producing a Reduce consensus and a USD 12.00 average price target. That target lies 2.3 percent above the USD 11.73 reference price, leaving limited implied upside in the published consensus.

Medifast reaffirmed fiscal 2026 revenue guidance of USD 270 million to USD 300 million and expects a loss per share of USD 0.25 to USD 1.75, according to Zacks on September 2, 2026. Management expects progress toward profitability to begin in Q4 2026 after the new product launch.

Stock remains below yearly high

Medifast had a market capitalization of USD 130.4 million and volume of 82,615 shares on October 2, 2026. Its USD 9.22 to USD 14.15 52-week range places the latest price USD 2.42 below the yearly high, while the loss-making profile keeps the revenue recovery central to the valuation debate.